Rediscovering alemtuzumab: Current and emerging therapeutic roles

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 818-831

  Gribben, John G ^a   Hallek, Michael ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Alemtuzumab; Chronic lymphocytic leukaemia; Lymphoproliferative disorders; Minimal residual disease; Monoclonal antibodies

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTIVIRUS AGENT; BETA1 INTERFERON; CD20 ANTIGEN; CD52 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; MELPHALAN; MYELOABLATIVE AGENT; RITUXIMAB; UNCLASSIFIED DRUG; VALACICLOVIR; VALACLOVIR; VALGANCICLOVIR;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG ASPERGILLOSIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYCOSIS; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PERIPHERAL T CELL LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SEZARY SYNDROME; T CELL LEUKEMIA; THROMBOCYTOPENIA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 60649093569     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07557.x     Document Type: Review

References (80)

1. Albitar, M., Do, K.A., Johnson, M.M., Giles, F.J., Jilani, I., O'Brien, S., Cortes, J., Thomas, D., Rassenti, L.Z., Kipps, T.J., Kantarjian, H.M. Keating, M. (2004) Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer, 101, 999 1008.
2. Ashraf, U., Elefante, A.N., Cruz, R., Wallace, P.K., Czuczman, M.S. Hernandez-llizaliturri, F.J. (2007) Emergence of rituximab-fludarabine resistance is associated with changes in CD20 antigen expression and improved response to alemtuzumab therapy in patients with chronic lymphocytic leukemia (CLL). Blood, 110, 612a (abstract 2054).
3. Beum, P.V., Kennedy, A.D., Williams, M.E., Lindorfer, M.A. Taylor, R.P. (2006) The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. Journal of Immunology, 176, 2600 2609.
4. Byrd, J.C., Lin, T.S. Grever, M.R. (2006) Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Seminars in Oncology, 33, 210 219.
5. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230 239.
6. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. Milligan, D.W. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 4357 4363.
7. Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuerth, S., Geary, J., Thuraisundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker, A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C., Goldstone, A.H. Mackinnon, S. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 99, 1071 1078.
8. Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J. Catovsky, D. (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood, 98, 1721 1726.
9. Delgado, J., Thomson, K., Russell, N., Ewing, J., Stewart, W., Cook, G., Devereux, S., Lovell, R., Chopra, R., Marks, D.I., Mackinnon, S. Milligan, D.W. (2006) Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood, 107, 1724 1730.
10. Dewald, G.W., Brockman, S.R., Paternoster, S.F., Bone, N.D., O'Fallon, J.R., Allmer, C., James, C.D., Jelinek, D.F., Tschumper, R.C., Hanson, C.A., Pruthi, R.K., Witzig, T.E., Call, T.G. Kay, N.E. (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 121, 287 295.
11. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1910 1916.
12. Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M. Engert, A. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology, 23, 7024 7031.
13. Elter, T., James, R., Wendtner, C.M., Stilgenbauer, S., Winkler, D., Ritgen, M., Hallek, M. Engert, A. (2008) Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: first safety analysis of the CLL2L trial of the German CLL Study Group. Journal of Clinical Oncology, 26, 15S. abstr 7053.
14. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 2920 2924.
15. Ferrajoli, A., O'Brien, S.M., Cortes, J.E., Giles, F.J., Thomas, D.A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D.P. Keating, M.J. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98, 773 778.
16. Ferrajoli, A., Wierda, W., Lapushin, R., O'Brien, S., Faderl, S., Browning, M.L. Keating, M. (2008) Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. European Journal of Haematology, 80, 296 298.
17. Gilleece, M.H. Dexter, T.M. (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807 812.
18. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J. Catovsky, D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research, 22, 185 191.
19. Golay, J., Manganini, M., Rambaldi, A. Introna, M. (2004) Effect of alemtuzumab on neoplastic B cells. Haematologica, 89, 1476 1483.
20. Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 25, 799 804.
21. Hale, G. (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy, 3, 137 143.
22. Hale, G. Waldmann, H. (1994) Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplantation, 13, 597 611.
23. Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J. Waldmann, H. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood, 62, 873 882.
24. Hale, G., Dyer, M.J., Clark, M.R., Phillips, J.M., Marcus, R., Riechmann, L., Winter, G. Waldmann, H. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2, 1394 1399.
25. Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J. Waldmann, H. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood, 92, 4581 4590.
26. Heit, W., Bunjes, D., Wiesneth, M., Schmeiser, T., Arnold, R., Hale, G., Waldmann, H. Heimpel, H. (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. British Journal of Haematology, 64, 479 486.
27. Hillmen, P., Skotnicki, A.B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C. Mayer, J. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 25, 5616 5623.
28. Hirst, C.L., Pace, A., Pickersgill, T.P., Jones, R., McLean, B.N., Zajicek, J.P., Scolding, N.J. Robertson, N.P. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology, 255, 231 238.
29. Isaacs, J.D., Manna, V.K., Rapson, N., Bulpitt, K.J., Hazleman, B.L., Matteson, E.L., St Clair, E.W., Schnitzer, T.J. Johnston, J.M. (1996) CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. British Journal of Rheumatology, 35, 231 240.
30. Karlsson, C., Norin, S., Kimby, E., Sander, B., Porwit, M.A., Nilsson, B., Johansson, E., Mellstedt, H., Lundin, J. Osterborg, A. (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia, 20, 2204 2207.
31. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. Rai, K.R. (2002a) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554 3561.
32. Keating, M.J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjonnfjord, G., Bekradda, M., Itzhaki, M. Herait, P. (2002b) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology, 20, 205 213.
33. Keating, M.J., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S. Kantarjian, H. (2002c) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia & Lymphoma, 43, 1755 1762.
34. Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J.C., Rosen, S., Dearden, C., Dyer, M.J. Hillmen, P. (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma, 4, 220 227.
35. Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G. Hillmen, P. (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 99, 2245 2247.
36. Kennedy, G.A., Seymour, J.F., Wolf, M., Januszewicz, H., Davison, J., McCormack, C., Ryan, G. Prince, H.M. (2003) Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. European Journal of Haematology, 71, 250 256.
37. Khorana, A., Bunn, P., McLaughlin, P., Vose, J., Stewart, C. Czuczman, M.S. (2001) A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leukemia & Lymphoma, 41, 77 87.
38. Kirchhoff, C. (1996) CD52 is the 'major maturation-associated' sperm membrane antigen. Molecular Human Reproduction, 2, 9 17.
39. Kline, J., Pollyea, D.A., Stock, W., Artz, A., Rich, E., Godley, L., Zimmerman, T., Thompson, K., Pursell, K., Larson, R.A. van, B.K. (2006) Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation, 37, 307 310.
40. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan, G.J., Hale, G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch, D.C., Goldstone, A.H. Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 96, 2419 2425.
41. Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. Stilgenbauer, S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 1410 1416.
42. Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T., Kienle, D., Winkler, D., Bangerter, M., Schlenk, R.F., Benner, A., Lichter, P., Dohner, H. Stilgenbauer, S. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 969 975.
43. Lozanski, G., Heerema, N.A., Flinn, I.W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M.L., Proffitt, J.H., Lucas, D., Grever, M.R. Byrd, J.C. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103, 3278 3281.
44. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 16, 3257 3263.
45. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768 773.
46. Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T. Osterborg, A. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, 4267 4272.
47. Mone, A.P., Cheney, C., Banks, A.L., Tridandapani, S., Mehter, N., Guster, S., Lin, T., Eisenbeis, C.F., Young, D.C. Byrd, J.C. (2006) Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia, 20, 272 279.
48. Montillo, M., Tedeschi, A., Miqueleiz, S., Veronese, S., Cairoli, R., Intropido, L., Ricci, F., Colosimo, A., Scarpati, B., Montagna, M., Nichelatti, M., Regazzi, M. Morra, E. (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 2337 2342.
49. Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology, 23, 2971 2979.
50. Morris, E. Mackinnon, S. (2005) Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfusion Apheresis Science, 32, 73 83.
51. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 3865 3871.
52. Nguyen, D.D., Cao, T.M., Dugan, K., Starcher, S.A., Fechter, R.L. Coutre, S.E. (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clinical Lymphoma, 3, 105 110.
53. Nuckel, H., Frey, U.H., Roth, A., Duhrsen, U. Siffert, W. (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. European Journal of Pharmacology, 514, 217 224.
54. O'Brien, S.M., Gribben, J.G., Thomas, D.A., Albitar, M., Wierda, W., Ferrajoli, A., Lerner, S., Kantarjian, H.M., Kipps, T. Keating, M.J. (2003a) Alemtuzumab for minimal residual disease in CLL. Blood, 102, 109a (abstract 371).
55. O'Brien, S.M., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F.J., Wierda, W.G., Koller, C.A., Ferrajoli, A., Browning, M., Lerner, S., Albitar, M. Keating, M.J. (2003b) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, 98, 2657 2663.
56. O'Brien, S., Ravandi, F., Riehl, T., Wierda, W., Huang, X., Tarrand, J., O'Neal, B., Kantarjian, H. Keating, M. (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood, 111, 1816 1819.
57. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 1177 1184.
58. Osterborg, A. Dyer, M.J. (2001) CAMPATH-1H in the treatment of lymphoid malignancies. In : Monoclonal Antibody Therapy of Hematologic Malignancies (ed. by B.D. Cheson pp. 135 150. Darwin Scientific Publishing Ltd, Abingdon, UK.
59. Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. Mellstedt, H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 93, 151 153.
60. Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567 1574.
61. Osuji, N.C., Del, G.I., Matutes, E., Wotherspoon, A.C., Dearden, C. Catovsky, D. (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica, 90, 1435 1436.
62. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 3121 3127.
63. Perkins, J.G., Flynn, J.M., Howard, R.S. Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94, 2033 2039.
64. Rai, K.R., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., Santabarbara, P., Wacker, B. Brettman, L. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology, 20, 3891 3897.
65. Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 29 35.
66. Rosenwald, A., Chuang, E.Y., Davis, R.E., Wiestner, A., Alizadeh, A.A., Arthur, D.C., Mitchell, J.B., Marti, G.E., Fowler, D.H., Wilson, W.H. Staudt, L.M. (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood, 104, 1428 1434.
67. Rowan, W., Tite, J., Topley, P. Brett, S.J. (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology, 95, 427 436.
68. Sayala, H.A., Moreton, P., Jones, R.A., Rawstron, A.C., O'Conner, S.J., Evans, P., Carter, A., Dearden, C., Matutes, E., Pettitt, A.R., Kennedy, D.B. Hillmen, P. (2006) Final report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with flduarabine- refractory CLL (on behalf of the NCRI CLL Trials Subgroup). Blood, 108, 14a 15a (abstract 34).
69. Stanglmaier, M., Reis, S. Hallek, M. (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Annals of Hematology, 83, 634 645.
70. Stilgenbauer, S. Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. New England Journal of Medicine, 347, 452 453.
71. Stilgenbauer, S., Winkler, D., Buhler, A., Zenz, T., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., lengfelder, E., Trumper, L., Soling, U., Schlag, R., Hallek, M. Dohner, H. (2007) Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood, 110, 918a (abstract 3120).
72. Tam, C.S., Wierda, W., O'Brien, S.M., Lerner, S., Abruzzo, L.V., Ferrajoli, A., Kantarjian, H.M. Keating, M.J. (2008) The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: a study of 180 consecutive patients. Journal of Clinical Oncology, 26, 380s (May 20 suppl., abstract 7035).
73. Uppenkamp, M., Engert, A., Diehl, V., Bunjes, D., Huhn, D. Brittinger, G. (2002) Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Annals of Hematology, 81, 26 32.
74. Waldmann, H., Polliak, A., Hale, G., Or, R., Cividalli, G., Weiss, L., Weshler, Z., Samuel, S., Manor, D. Brautbar, C. (1984) Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet, 2, 483 486.
75. Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B. Hallek, M. (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia, 18, 1093 1101.
76. Wierda, W.G., O'Brien, S., Faderl, S., Ferrajoli, A., Ravandi-Kashani, F., Cortes, J., Giles, F., Andreeff, M., Koller, C.A., Lerner, S., Kantarjian, H. Keating, M.J. (2006) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood, 108, 14a (abstract 31).
77. Wierda, W.G., O'Brien, S., Ferrajoli, A., Faderl, S., Koller, C., Estrov, Z., Garcia-Manero, G., Verstovsek, S., Browning, M., Learner, S. Keating, M. (2007) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood, 110, 628a (abstract 628).
78. Xia, M.Q., Hale, G., Lifely, M.R., Ferguson, M.A., Campbell, D., Packman, L. Waldmann, H. (1993) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemical Journal, 293, 633 640.
79. Zenz, T., Ritgen, M., Dreger, P., Krober, A., Barth, T.F., Schlenk, R., Bottcher, S., Hallek, M.J., Kneba, M., Bunjes, D., Dohner, H. Stilgenbauer, S. (2006) Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood, 108, 2127 2130.
80. Zinzani, P.L., Alinari, L., Tani, M., Fina, M., Pileri, S. Baccarani, M. (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica, 90, 702 703.